Semiconductor versus graphene quantum dots as fluorescent probes for cancer diagnosis and therapy applications by Rakovich, Aliaksandra & Rakovich, Tatsiana
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1039/C8TB00153G.
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Rakovich, A., & Rakovich, T. (2018). Semiconductor versus graphene quantum dots as fluorescent probes for
cancer diagnosis and therapy applications. Journal of materials chemistry b, 2690-2712 .
https://doi.org/10.1039/C8TB00153G.
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
This is an Accepted Manuscript, which has been through the  
Royal Society of Chemistry peer review process and has been 
accepted for publication.
Accepted Manuscripts are published online shortly after 
acceptance, before technical editing, formatting and proof reading. 
Using this free service, authors can make their results available 
to the community, in citable form, before we publish the edited 
article. We will replace this Accepted Manuscript with the edited 
and formatted Advance Article as soon as it is available.
You can find more information about Accepted Manuscripts in the 
author guidelines.
Please note that technical editing may introduce minor changes 
to the text and/or graphics, which may alter content. The journal’s 
standard Terms & Conditions and the ethical guidelines, outlined 
in our author and reviewer resource centre, still apply. In no 
event shall the Royal Society of Chemistry be held responsible 
for any errors or omissions in this Accepted Manuscript or any 
consequences arising from the use of any information it contains. 
Accepted Manuscript
rsc.li/materials-b
Journal of
 Materials Chemistry B
Materials for biology and medicine
www.rsc.org/MaterialsB
ISSN 2050-750X
PAPER
Guoping Chen et al.
Regulating the stemness of mesenchymal stem cells by tuning 
micropattern features
Volume 4 Number 1 7 January 2016 Pages 1–178
Journal of
 Materials Chemistry B
Materials for biology and medicine
View Article Online
View Journal
This article can be cited before page numbers have been issued, to do this please use:  A. Rakovich and T.
Rackovich, J. Mater. Chem. B, 2018, DOI: 10.1039/C8TB00153G.
	









Page 1 of 25 Journal of Materials Chemistry B
Jo
ur
na
lo
fM
at
er
ia
ls
C
he
m
is
tr
y
B
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
10
 A
pr
il 
20
18
. D
ow
nl
oa
de
d 
by
 K
in
gs
 C
ol
le
ge
 L
on
do
n 
on
 1
1/
04
/2
01
8 
14
:1
4:
30
. 
View Article Online
DOI: 10.1039/C8TB00153G
Journal Name
Semiconductor versus graphene quantum dots as flu-
orescent probes for cancer diagnosis and therapy ap-
plications
Aliaksandra Rakovich,∗a,b and Tatsiana Rakovichc
Early diagnosis of cancer is of critical importance in determining the outcome of a patient, and
nanoparticulate fluorophores have been at the centre of research for such applications owing to
their superior optical properties. Furthermore, the large surface area to volume ratios of these flu-
orophores enables them to be endowed with several modalities, including the targeting of specific
biomarkers and drug delivery capabilities, promoting them as therapeutic agents as well. Over
the last few decades, semiconductor quantum dots have dominated the field due to their unique
yet well characterised optical properties. However, the scope of their application for diagnosis and
therapy of cancer has been hindered by declarations of in vivo toxicity attributed to heavy metals
typically found in their composition. Recent arrivals graphene quantum dots, or carbon-derived
counterparts to SQDs, are often claimed to be biocompatible but they have complicated optical
properties. In this review, we compare the properties of these two types of quantum dots in view
of their employment as fluorescent agents for cancer diagnosis and therapy.
1 Introduction
A few years ago, the UK media made an announcement that the
lifespan of over half of new cancer patients would be extended
by a decade1; this means that the average 10-year survival rate
in the UK would finally increase to 50%! Indeed, for the UK the
overall trend across decades has been one of declining mortality
rates2 (Figure 1a, data in red), which is attributed to the great
therapeutic advances and improvements in diagnostic methods,
the latter also being largely responsible for detection of the rising
amounts of cancer incidences in the last few decades (Figure 1a,
data in blue). However, this view can be misleading, as can be
evidenced by similar time trends for the four most occurring can-
cer types: lung, breast, bowel, and prostate. For example, the net
survival rates for breast and prostate cancers have both increased
to 80% by 2010, and so they weigh heavily in the statistics (blue
and green bars in Figure 1b). On the other hand, the survival rate
for lung cancer has remained below 5% (red bars in Figure 1b),
despite the extraordinary advances in oncology mentioned above.
Great insight into this discrepancy can be gained by examining
the stage of cancer development at which it is more likely to be
a Photonics and Nanotechnology Group, Department of Physics, King’s College London,
London, United Kingdom. Tel: 02 07848 7328; E-mail: aliaksandra.rakovic@kcl.ac.uk
b Experimental Solid State Group, Department of Physics, Imperial College London,
London, United Kingdom.
c Department of Molecular Rheumatology, Trinity Biomedical Sciences Institute, Trinity
College Dublin, Dublin 2, Ireland.
diagnosed. Both breast and prostate cancer have a higher inci-
dence of cancers diagnosed at stage I compared to lung cancers,
which are most likely to be diagnosed at stage IV, i.e. when it
has already metastasized throughout the body (Figure 1c). This,
combined with higher survivability rates for earlier stages of can-
cer (Figure 1d), elucidates the criticality of early diagnosis - it is
the single most important factor in determining the outcome for
the patient.
Several factors can promote early diagnosis. Public aware-
ness can be raised about the symptoms and the simple do-it-at-
home self-checks, as has been the case for breast cancer. Also,
the availability of simple screening methods based on detection
of biomarkers in blood samples could be increased, as was the
case for prostate cancer around 1990 when PSA testing was in-
troduced (indicated by * in Figure 1b), correlating with the jump
in the net survivability rates for prostate cancer from pre-1990 to
post-2000 (Figure 1b). These, however, are special cases of eas-
ily accessible and commonly occurring cancers. The vast majority
of cancer types do not fall within this category, and it is in these
cases where major scientific advances are urgently needed.
Among various types of diagnostic detection methods,
fluorescence-based techniques offer unique practicalities, such as
high sensitivity, specificity, activatable signal and multiplexing ca-
pabilities, fast acquisition times, and the widespread availabil-
ity and relatively low cost of instrumentation3,4. Such detection
techniques rely on the use of a fluorophore, which traditionally
has been a molecular dye. However, a vast amount of research in
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Fig. 1 Cancer incidences and mortality rates in the United Kingdom. Panel (a) shows incidences of diagnosis of cancer per 100,000 of
population (blue lines) and subsequent mortality rate (red lines) for men (solid lines) and women (dashed lines) in UK from 1980 to 2015. Panel (b)
shows the net 10-year survival percentage for four most commonly diagnosed cancer types from 1971 to 2010. The bottom panels show proportion of
total diagnosis made (c) and the relative 5-year survival percentage (d) per stage of cancer progression. Data obtained from Cancer Research UK,
http://www.cancerresearchuk.org/health-professional/cancer-statistics/, accessed January 2017.
Fig. 2 Diagramatic representation of the structures of graphene
(a) and semiconductor (b) quantum dots. The two types of quantum
dots both have similar sizes (Table 1), and are stabilised by hydrophilic
groups attached to their surfaces/edges (yellow squares/spheres). The
core of the GQDs consist of a single or few layers of grapene sheets.
SQDs have inorganic cores (red), sometimes surrounded by a shell of
another inorganic material (orange). They may also be encapsulated in
additional layer for stability purposes or to reduce the toxicity of
heavy-metal containing SQDs.
the cancer detection field in the last few decades has been dom-
inated by colloidal semiconductor Quantum Dots (SQDs). These
are nanometre-sized crystals of semiconductor materials such as
CdSe, ZnS, InP, and PbSe kept in solution through the attachment
of stabilising ligands to their surfaces (Figure 2b). They have very
appealing size-dependent optical properties, including symmetric
emissions and high fluorescence quantum yields4,5. Their popu-
larity over the years for in vitro bioimaging and immunosensing
assays is a reflection of these properties6,7, and thus many re-
gard SQDs to be at the forefront of the race for the development
of next-generation medical diagnostic tools. Likewise, the large
surface area to volume ratios of SQDs presents an exciting oppor-
tunity for the attachment of multiple agents to their surfaces to
yield combined diagnostic and therapeutic modalities. However,
many consider SQDs unsuitable for in vivo applications due to re-
ports of toxicity issues relating to the presence of heavy metals
commonly found in their composition8–10. In addition, the avail-
ability of said elements in nature is relatively low and therefore
SQDs are considered to be expensive. It should be noted that
these claims are gross generalisations, especially in view of the
2 | 1–24Journal Name, [year], [vol.],
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limited amount of comprehensive studies published on the top-
ics. Nevertheless, they have somewhat obstructed the translation
of SQDs to therapeutic and diagnostic applications.
Carbon, on the other hand, is abundant, inexpensive and is
generally considered to be biocompatible. Although the link
between material composition and its biocompatibility is not
straightforward, graphene Quantum Dots (GQDs) – or carbon
equivalents to SQDs – have emerged as potential alternatives.
GQDs are generally described as a single- to few-layer patches
of graphene sheets, with lateral dimensions in the nanometre
range11 (Figure 2a). They offer many exciting opportunities
for drug delivery and photodynamic therapy, as will be dis-
cussed in later sections, but do have complicated fluorescence
behaviour12–16. Despite this fact, and an almost complete lack
of information about their in vivo toxicity, they have already es-
tablished themselves as significant contenders in the field.
In this review, we compare the properties of two types of quan-
tum dots in the context of using them as fluorescent labels for
diagnosis and therapy of cancer. As a reference, we use the guid-
ing principles of Resch-Genger et al.4 for a suitable label, which
include: (1) the optical properties of the probes, such as their
brightness, photostability and convenient excitation; (2) their
chemical properties such as the solubility, stability under exper-
imental or physiological conditions, availability of chemical mod-
ification strategies for labelling and drug loading; (3) the poten-
tial toxicity and biocompatibility of the label. We should note that
the aim of this review is not to deliver an extensive summary of
the literature, but rather to provide a critical comparison of the
two quantum dots types in order to facilitate the choice between
them for a particular application. There exist a great number of
reviews for both types of quantum dots, and where possible, the
reader is directed to them for more detailed accounts of specific
topics.
2 Comparison of optical properties
The optical properties relevant to the application of quantum dots
as fluorescence probes include their linear optical properties, such
as the wavelength and quantum yield of their emission, and their
absorption properties in the visible and the biologically-significant
spectroscopic ranges, and their photostability. Other properties
that may be significant for some applications are the shape of
their photoluminescence bands, emission anisotropy (polarisa-
tion dependence), the fluorescence lifetime, and the non-linear
absorption properties.
2.1 Origin of photoluminescence
When a semiconductor material absorbs a photon, an electron is
promoted from the valence band to the conduction band, leav-
ing behind a hole. Being of opposite charges, the electron-hole
pair weakly binds to form a hydrogen-like quasi-particle called
exciton, that has a corresponding binding radius called the exci-
ton Bohr radius. In SQDs, the size of the particle is smaller than
the Bohr radius, resulting in quantum confinement of the exciton
and quantisation of its energies, the latter being inversely propor-
tional to the size of the quantum dot17–20. Optical excitations be-
Fig. 3 Size-dependent optical properties. (a) The energy bandgap of
SQDs as a function of their size is illustrated using data for CdSe
quantum dots from two references 17,18. Both sets of data do not
significantly deviate from the expected 1/d2 dependency (black line). (b)
and (c) illustrate the effect the edge geometry has on the bandgap of
graphene-derived materials. (b) was obtained using electrical
measurements on graphene nanoribbons and (c) are theoretical
calculations for hexagonal GQDs. (b) was adapted from K.A. Ritter et
al. 12. (c) was adapted from Z. Z. Zhang et al. 16
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tween these discreet states give rise to the distinctive absorption
spectra of SQDs, and band-edge recombination from the lowest
excited state yields the characteristically narrow and symmetric
emissions. It is important to point out that, for SQDs, the proba-
bility density for the excited electron is largest inside the confin-
ing potential and very small at its edge21,22, i.e. at the surface of
the quantum dot. Hence, for a well-confined SQD, its main op-
tical properties, such as the emission wavelength and absorption
spectrum, are defined primarily by its bulk, i.e. by the constituent
material, its crystallinity, size, and shape. The photoluminescence
quantum yield (PLQY) of the SQDs can be affected by changes to
its surface, for example, through the creation of surface defects
leading to the existence of non-radiative trap states23–25. Nev-
ertheless, further chemical modification of well-passivated SQDs
does not modify their optical properties significantly4,26, typically
resulting in a slight decrease of their PLQY and sometimes in a
slight shift of their photoluminescence band (usually of the order
of 10 nm).
Graphene is a zero-bandgap semiconductor, and the lack of
the bandgap prohibits fluorescence in extended graphene struc-
tures. However, graphene can be made fluorescent by opening up
a bandgap, which can be achieved in several ways, e.g. through
the introduction of structural defects, the creation of small “sp2
islands“ or the reduction graphene sheet size27–30, as is the case
for GQDs. In general, fluorescence in graphene-derived nano-
materials is attributed to two origins15: (a) transitions between
states associated with the conjugated pi-domains (islands of sp2
hybridisation character), similar to those found in large aromatic
molecules; (b) defect-derived fluorescence, where the defect can
either be electronically coupled to or act as a perturbation centre
of the aromatic network.
The bandgap transitions in origin (a) are highly sensitive to
their environment — any disturbance of the conjugated domains
leads to a decreased efficiency of bandgap fluorescence; for ex-
ample, the addition of the second layer of graphene strongly
quenches said transitions28. Furthermore, even for pristine
single-layer GQDs, the size-fluorescence relationship is more com-
plex than for the case of SQDs due to the “quasi-molecular“ na-
ture of the fluorescence14,31. For example, nano-sized graphene
pieces of similar sizes can have different bandgap energies de-
pending on which type of edge is predominant in the struc-
ture (Figure 3)12,16. Moreover, and in contrast to SQDs, the
ground states of the conduction and valence bands of nano-sized
graphene have a non-zero value at their edges16. Therefore, any
chemical modification of the edge groups, e.g. for solubility or
functionalisation purposes, has the potential to affect the optical
properties of GQDs. In practical terms, this means that, when
designing fluorescence GQD probes, any post-synthesis chemical
modifications must be taken into account. On the other hand, this
effect has been exploited to enhance the fluorescence of GQDs
by doping or edge functionalisation - the addition of strong elec-
tron donating or accepting moieties can strongly disturb the lo-
cal electronic environment and modify the optical behaviour of
GQDs32–34. Such defect-derived fluorescence tends to be much
stronger than the bandgap transitions discussed above; in fact, it
has been suggested that most of the strongly fluorescent GQDs
have this type of emission15. In fact, one can argue that in most
of the reports on fluorescent GQDs, this is the dominant type of
photoluminescence mechanism, since no clear correlation exists
between the lateral size of the colloidal GQDs and the energy of
their emission (see Figure 4a).
2.2 Quantum dot brightness
The brightness of a fluorophore is defined as the product of its ex-
citation cross-section (or extinction coefficient) at the excitation
wavelength and its quantum yield. Effectively, it is a measure of
the fluorescence signal that can be obtained with the given fluo-
rophore and, along with some other parameters such as the width
of emission, it has an influence on the resolution and contrast that
can be obtained in bioimaging applications. A key point to take
away from this is that the use of the fluorophore for bioimaging
is determined by both its absorption and emission properties, and
factors that influence both must be taken into account. It is there-
fore very unfortunate that in the majority of reports on the use of
GQDs for these purposes, the authors fail to state the absorption
coefficient of the sample. In fact, in our literature search for this
review, we have come across only two that state this value: L.
Wang et al.33 reported a value of ∼106 M-1 cm-1 at ∼400 nm ex-
citation for GQDs emitting at 480 nm with a 45% Quantum Yield,
while X. Yan et al.35 reported a value of 105 M-1 cm-1 at the low-
est energy peak (600 nm) and at 400 nm but did not report the
emission characteristics of the sample. Ignoring the discrepancy
of the order of magnitude between the two extinction coefficients
quoted, these values are similar or lower to those reported for
SQDs in similar wavelength ranges.
For example, as a measure of like-to-like comparison, the ex-
tinction coefficient of CdS SQDs emitting at 480 nm (∼5.3 nm in
size) is just under 106 M-1 cm-1 at 400 nm (according to W. W.
Yu et al.18). Aqueous CdS SQDs with near unity quantum yields
have been previously synthesised36, making SQDs in this report
slightly brighter than GQDs synthesised by L. Wang et al.33.
The data in Figure 4 suggests that quite a significant portion
of GQDs synthesised emit in the 500-600 nm region, hence it
would be interesting to compare the brightness of these GQDs
to SQDs. However, no extinction data is available for this wave-
length range for GQDs, and so only estimates can be made. Based
on the extinction values quoted above and data in Figure 4 for
GQDs, the extinctions of SQDs and GQDs in the 500-600 nm spec-
tral region are expected to be comparable, while the PLQY to be
slightly higher for SQDs. On average, the expectation is that the
two types of Quantum Dots would have similar brightness in this
wavelength range.
For visible wavelengths above 600 nm, the extinction coeffi-
cients of SQDs are higher than those reported by X. Yan et al.35
for GQDs: CdSe/ZnS SQDs with a first excitonic peak at 600 nm
have an extinction coefficient of the order of 106 M-1 cm-1 and
2-3 times larger at 400 nm18. Furthermore, CdSe-based SQDs
have consistently high PLQYs in this wavelength region (typi-
cally > 50%)37–40 but have also been synthesised with near-unity
PLQYs41. In contrast, very few GQDs have been synthesised with
emissions above 600 nm (Figure 4a), and none of those report
4 | 1–24Journal Name, [year], [vol.],
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Fig. 4 Optical properties of synthesised graphene quantum dots. (a) Energy (scale on the left) and wavelength (scale on the right) of
photoluminescence and (b) photoluminescence quantum yield as a function of lateral size of synthesised GQDs. Inset of (b) compares the quantum
yield and wavelength of emission of GQD samples — no correlation between these parameters can be seen. Data points in blue are for non-doped
GQDs with oxygenated end groups, those shown in red are for nitrogen-doped GQDs or GQDs with N-containing end groups. Data for both plots is
summarised in Table 2.
their PLQY values. However, based on the data for typical GQDs
(Figure 4b), their PLQY values in this region are expected to be
below 50%. Therefore, the brightness of SQDs is expected to be
almost an order of magnitude larger in this wavelength region.
Finally, the near-infrared (NIR) spectral region is of particular
importance for bioimaging in vivo, since absorption by physio-
logical fluids is minimal in this region allowing for deeper tissue
visualisation42. The SQDs and GQDs have been proposed as suit-
able probes for these applications, although the literature for both
is rather limited making the comparison between the two imprac-
tical.
For GQDs, M. Nurunnabi et al.43 reported on the synthesis of
NIR GQDs from carbon fibre, in which the temperature of the re-
action could be used to control the wavelength of the emission:
for temperatures below 80oC GQDs emitting in the NIR were pro-
duced. Neither the extinction coefficient nor the PLQY of the
GQDs was stated in this case. L. Tang et al.44 synthesised heav-
ily N-doped GQDs which had three distinct photoluminescence
peaks, including one in the NIR region which shifted depending
on the size of the particle. In this case, the authors do quote the
PLQY of ∼11.3%, however, this value is for the emission in the
visible and not in the NIR region.
For SQDs, S. Kim et al.45 used type II CdTe/CdSe SQDs for sen-
tinel lymph node mapping during a surgical procedure on small
and large animals. The quantum yield of these QDs was 13%,
and their extinction coefficient at first excitonic peak was ∼6x105
M-1 cm-1. W. Cai et al.46 employed very large CdTe SQDs for
in vivo imaging of integrin αVβ3-positive tumor vasculator in a
murine xenograft model. Neither PLQY nor an extinction coef-
ficient are stated, but the latter can be estimated to be ∼5x105
M-1 cm-1 (according to W. W. Yu et al.18). J. P. Zimmer et al.47
developed a method to synthesise core-shell InAs/ZnSe SQDs of
various sizes that emit in the NIR, and then utilised these SQDs
for sentinel lymph node mapping and extravasation from the vas-
culature in rat models. The synthesised SQDs had relatively low
PLQYs of 6-9% after solubilisation in aqueous solution. The ex-
tinction coefficient of these SQDs is not mentioned in the paper,
but typical values for InAs SQDs are of the order of 105 M-1 cm-1
at these wavelengths48. More recently, J. Park et al.49 developed
water-soluble NIR SQDs that did not have toxic elements in their
composition and showed their applicability for in vivo biomedical
imaging using a mouse model. These SQDs had relatively high
extinction coefficients of ∼3x106 M-1 cm-1 and good PLQYs of
20-30%, making them one of the best NIR probes to date.
2.3 Nonlinear optical properties
Multiphoton microscopy (MPM) is another type of imaging that
makes use of increased transparency in the NIR region. One can
think of it as a reverse of NIR imaging — the fluorophore is ex-
cited in the NIR but emits in the visible spectrum. Such upcon-
version, i.e. an increase in the energy of the emission relative to
the excitation energy, can be due to multiple absorptions of low-
energy photons involving virtual levels or defect-states, and these
optical processes have nonlinear dependencies on the intensity of
the excitation laser (∝ I2 for two-photon absorption) leading to
improved resolution of the technique compared to NIR imaging.
Other advantages of MPM include higher quantum efficiencies
and reduced photobleaching of fluorescent probes, reduced pho-
todamage of biological tissues and minimised autofluorescence
backgrounds50,51. The suitability of the fluorescent probe for
MPM applications is often judged based on its multi-photon ab-
sorption cross-section (σ); for two-photon processes this is gen-
erally expressed in units of Göeppert-Mayer (GM).
Based on the tunability of their emission, high two-photon
absorption cross-sections and very high quantum yields in the
visible, SQDs have long been considered for these applica-
tions52,54–65. However, only a few examples exist of their appli-
cation in cancer research and even fewer reference the nonlinear
absorption cross-sections of SQD samples used. For example, D.R.
Larson et al.52 used MPM to image CdSe SQDs hundreds of mi-
Journal Name, [year], [vol.],1–24 | 5
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Fig. 5 Quantum dots as fluorescent probes for multi-photon microscopy. (a) Two-photon fluorescence microscopy of living mice tissues using
CdSe SQDs with yellow emission, showing (A) capillaries at the base of the dermis, (B) a series of line-scan measurements across the region
indicated in A, from which blood flow velocity was calculated, and (C) zoom section of B where undulations of capillary walls due to heartbeat are
clearly visible. The blue background in (A) is due to second harmonic generation by collagen at 450 nm. Adapted from D.R. Larson et al. 52. Reprinted
with permission from AAAS. (b) One-photon (top row) and Two- photon (bottom row) fluorescence imaging (OPFI and TPFI respectively) of intralipid
mock tissues at different depths, increasing left-to-right, using N-GQDs as probes. Adapted with permission from Q. Liu et al. 53. Copyright (2017)
American Chemical Society.
crometres below the skin of living mice and were able to visualise
capillaries, measure blood flow and estimated the heart rate of
mice from undulations of the capillary walls (Figure 5a). They
reported action cross-sections (product of σ and PLQY) of up to
47,000 GM for these QDs, depending on the excitation wave-
length. Since the PLQYs are less than 1.0, the actual values of
σ are expected to be even higher, i.e. close to the theoretical
value for CdSe QDs of 50,000 GM66. More recently, H. Hafian
et al.61 have employed CdSe/ZnS SQDs conjugated with single-
domain antibodies for two-photon imaging of carcinoembryonic
antigen in human appendix and colon carcinoma tissue sections.
While the depth of the imaging, in this case, was relatively low,
the study does demonstrate the pertinence of this technique to
discrimination of normal and cancerous tissues. The probes used
in this study had σ of up to 49,000 GM.
As far as GQDs are concerned, a number of reports have been
published demonstrating upconversion in GQDs34,69–71, but only
two report their use for MPM imaging. In 2013, Q. Liu et al.53 re-
ported very high two-photon absorption cross-sections of 48,000
GM for N-doped GQDs excited at 780 nm, which they then
utilised for MPM of HeLa cells at relatively low incident power.
Furthermore, using intralipid mock tissue, they estimated the
maximum penetration depth of the technique with their probes to
be as large as 1800 µm (Figure 5b). In 2016, W.-S. Kuo72 et al.
developed an integrated method based on two-photon excitation
of GQDs to simultaneously localise bacteria at a specific depth
in a three-dimensional environment and eliminate the targeted
bacteria using the photo-induced production of reactive oxygen
species. The authors report a comparable value for two-photon
absorption cross-section for their GQDs of 47,903 GM. Taking into
account the random orientation of GQDs in these samples, both
values are still about an order of magnitude lower than the theo-
retical estimates (>106 GM)73 leaving a lot of room for improve-
ment. Therefore, GQDs have great potential to become the pre-
ferred option for applications in MPM. However, as things stand
at the moment, their nonlinear cross-sections are similar to those
6 | 1–24Journal Name, [year], [vol.],
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Fig. 6 Shape of photoluminescence bands of semiconductor (a) and graphene (b,c) quantum dots. (a) The symmetric photoluminescence
profiles of four CdTe quantum dot samples of increasing diameters (the range of average diameters is indicated on the figure). (b) An example of a
symmetric emission from GQDs. Reprinted from D. Pan et al. 67 with permission. (c) An example of asymmetric emission: the triple-picked
photoluminescence profile of N, F and S co-doped quantum dots reported by S. Kundu 68. Reprinted with permission. GQDs in (b) show a shift in
photoluminescence position depending on excitation wavelength, while in those in (c) only vary in intensity (excitation wavelengths for both are shown
in the legend).
of SQDs while their PLQYs are slightly lower (see above section),
making their two-photon action cross-sections slightly lower too.
2.4 Shape of photoluminescence bands
While the shape of the PL band of the fluorescent label may be
of reduced importance in bioimaging, it gains prominence in ap-
plications involving multiplexed detection, which rely on the de-
convolution of contributions from individual channels. In this
respect, SQDs have gained immense reputation due to their sym-
metric emission profiles (Figure 6a), originating from the charac-
teristic band-edge emissions, broadened by the Gaussian distribu-
tion of their sizes in a typical colloidal sample. Recently, D. Ren
et al. used two SQD samples simultaneously, one labeled with
epidermal growth factor (EGF) and the other with the antibody
against the epidermal growth factor receptor (EGFR). This was
done in order to study what role EGFR plays in preventing HeLa
cells from engulfing EGF and in inhibiting the overproliferation
of the cells74. Q. Xu et al. used triplexed Förster Resonance En-
ergy Transfer (FRET)-based detection to develop a chemical ’nose’
for differentiation of serum proteins and cell lines. Their multi-
plexed sensing platform was able to correctly distinguish between
ten different serum proteins, seven proteins in human serum and
identify seven human cell lines, six of which were cancerous, all
without the need for a spatial array separation and at single exci-
tation wavelength75. Similarly, X. Qiu and N. Hilderbrandt used a
time-gated FRET between a Tb complex and three appropriately-
labeled SQDs to simultaneously detect three corresponding mi-
croRNA biomarkers. The triplexed detection assay required no
washing or separation steps and achieved a sensitivity of ∼0.2
nM76. For earlier examples and further details on the use of SQDs
for multiplexed applications, readers are directed to the reviews
from E. Petryayeva et al.77 and G. Rousserie at al.78; in addi-
tion, the book chapter by N. Hildebrandt and D. Geißler in ”Nano-
Biotechnology for Biomedical and Diagnostic Research” includes
FRET-based multiplexed diagnostic applications of SQDs79.
In contrast to SQDs, the vast majority of GQDs are reported to
have asymmetric emission profiles (Table 2), originating from the
”quasi-molecular” electronic structure of GQDs discussed above.
Furthermore, chemical functionalisation of edges or doping of
GQDs, e.g. to enhance their PLQY, can add to the complexity
of the PL shape. For example, S. Kundu et al. synthesised N,
F and S co-doped GQDs that had a triple-peaked emission (Fig-
ure 6c)68. However, some examples of symmetric photolumines-
cence bands of GQDs have been reported in the literature (Fig-
ure 6b and Table 2). Regarding colour-multiplexed applications
of GQDs, the situation is further complicated by the excitation
wavelength-dependent emission often observed with GQDs. The
proposed origin of this effect is an optical selection of different
electronic states associated with various surface defects of GQDs
and/or selection of differently-sized GQDs as the excitation wave-
length is scanned80–82. The difficulty in accounting for these pho-
toluminescence characteristics, and their variability across differ-
ent samples, makes multiplexed application of GQDs difficult, and
this has been reflected by a lack of work in this area. Perhaps the
only application of GQDs for multiplexed detection relating to
cancer diagnosis to date has been that reported by Z. S. Qian et
al. who developed a dual-sensor platform for simultaneous detec-
tion of DNA and bovine α-thrombin. In this work, two GQDs were
bonded with a specific oligonucleotide sequence and a thrombin
aptamer respectively and then stacked on top of a graphene ox-
ide sheet to provide the multiplexed ”on-off-on” type detection
platform83.
2.5 Fluorescence lifetimes
Fluorescence lifetime is broadly defined as the average time a flu-
orophore spends in an excited state, or equivalently, the time for
the excited state population to decay to 1/e via all possible ra-
diative and non-radiative channels109. An interesting feature of
the fluorescence lifetime is that it is much more sensitive to the
local physicochemical environment of the fluorophore compared
to its other optical properties4,110. Hence, parameters such as
the local pH and temperature, the presence of ions and metabo-
lites, and any interactions between the fluorophore and proteins,
membranes, photosensitisers, etc. can all be visualised110–112,
providing a sensitive measure of the intra-cellular environment.
Furthermore, fluorophores of different types tend to have widely
different fluorescence lifetimes; hence, concurrent intensity and
lifetime measurements can be used to easily deconvolve (or un-
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Table 1 Comparison of optical properties of semiconductor and graphene quantum dots
Property Semiconductor QDs Graphene QDs
Range of emission Tunable from 400 to 1400 nm Typically 400-600 nma
Shape of emission spectrum Symmetric emission bands with Gaussian profiles Generally asymmetric, ”quasi-molecular”
(size dispersion related)
FWHM of emission spectrum 20-50 nm in the visible FWHM typically <100 nm
50-100 nm in the NIR
Excitation dependence Emission position does not vary significantly Excitation-wavelength dependent emission likely
Polarisation dependence No inherent dipole - all polarisations equivalet Some polarisation dependency
(in and out of plane of graphene sheets)
De-excitation behaviourb Typically multi-exponentialc Typically multi-exponential
Average lifetimes 10-100 ns Average lifetimes 1-10 ns
Quantum Yield Visible: typically 40-70%; up to 95% Visible: typically 5-25%; up to 45%
NIR: typically 20-40%; up to 80% NIR: no data
Molar extinction coefficient 105-106 M-1 cm-1 at first excitonic peak 105-106 M-1 cm-1 at first excitonic peak
Two-photon cross-section Up to 49,000 GM Up to 48,000 GM
Stokes shift Up to 100 nm Typically 70-120 nm
Photostability High; can observe photobrightening High; can observe photobrightening
a Heavily doped GQDs have been shown to have fluorescence outside this range
b FLIM applications require contrast with autofluorescence, whose lifetime is typically of the order of 1-2 ns
c Behaviour can be monoexponential when surface of QDs is fully passivated
Fig. 7 Mercaptopropionic acid (MPA)-capped CdSe/ZnS quantum dots as intracellular pH sensors. (a) Fluorescence lifetime of MPA-SQDs as
a function of pH of the synthetic intracellular buffer. FLIM image (b) and lifetime distribution (c) of MC3T3-E1 cells before (i) and after incubation with
MPA-SQDs with nigericirin and buffers at pH 4.87 (ii) and 8.14 (iii). Reprinted with permission from A. Orte et al. 84 Copyright 2013 American
Chemical Society.
mix) fluorescence images into contributions from different fluo-
rophores even if they emit in the same spectral range, and/or to
improve the contrast between different channels in multiplexed
applications. This is of particular consequence in bioimaging,
where autofluorescence can contribute strongly across a wide
spectral range113,114.
It is surprising, therefore, that these opportunities have re-
mained largely unexplored for both types of quantum dots, de-
spite the fact that their lifetimes are significantly larger than that
of the autofluorescence (Table 1), and so both are well suited for
fluorescence lifetime imaging microscopy (FLIM) studies involv-
ing cancerous cells. To date, no such investigations have been
reported for GQDs and very limited literature exists for SQDs.
The work by Grecco et al. was perhaps the earliest example of the
application of SQDs to image a signal transduction process in live
cells115. Specifically, they used CdSe/ZnS quantum dots to moni-
tor clathrin-mediated transferrin-endocytosis in A431 cells in real
time. Furthermore, they demonstrated the possibility of lifetime
discrimination between the fluorescence of SQDs and the largely
overlapping fluorescence of Citrine in live cells. J. Conroy et al.
investigated the mechanisms behind the tropism of TGA-capped
CdTe to nuclei and nucleoli of THP1 cells, concluding that it may
be mediated by the binding affinity of these SQDs to biopolymers
within the nuclear compartments, such as core histones and nu-
clear lysates116. More recently, A. Orte et al.84 used CdSe/ZnS
SQDs as pH-sensitive fluorescent probes to visualise various intra-
cellular regions in MC3T3-E1 and CHO-k1 cells (Figure 7).
2.6 Photostability
High photostability is one of the key requirements for a fluores-
cent label, especially for those applications requiring long acqui-
sition time. In general, both SQDs and GQDs are considered to be
very good in this regard, however, both can show photo-induced
reduction117–120 or enhancement33,121–123 of fluorescence de-
pending on the type of the quantum dot, the level of surface pas-
sivation and presence of any encapsulation layers. Neither of the
8 | 1–24Journal Name, [year], [vol.],
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Table 2 Summary of optical properties of some synthesised graphene quantum dots
Probe type Dav (nm) / Emission Shape of PL band Excitation Stokes Quantum Lifetime Ref
height (nm) position dependence shift (nm) Yield (ns)
COOH-GQD 7.1/— 490 nm Asymmetric Not stated ∼100 3.9% 85
NH2-GQD 6.3/— 440 nm Asymmetric ∼100 8.5%
GQD 3.5/1.5 540 nm Asymmetric Yes >60 9.2% 86
NH2-GQD 4/— 440 nm Asymmetric / shoulder Yes 96 17.6% 5.7 83
GQD 4 / — 430 nm Asymmetric / shoulder 92 20.4% 2.1
PEG-GQD 60/2.5 510 nm Asymmetric Yes 110 3.8% 87
GQD 3/1.4 434 nm Asymmetric Yes 116 3.56 88
6/1.4 500 nm Asymmetric 169
9/1.4 564 nm Asymmetric 135
NH2-GQD 3.8/2 540 nm Almost symmetric Yes 50 7% 33
NHNH2-GQD 2.9/0.81 480 nm Almost symmetric 70 45% 7.26
OH-GQD 2.6/1.07 450 nm Almost symmetric 80 21%
GQD 9.6/1.5 430 nm Symmetric Yes 110 6.9% 67
GQD 4.5/— 510 nm Extremely narrow peak Not stated 89
PEG-GQD 6.6/1.5 420 nm Slight shoulder Not stated 90 4% 90
NH2-GQD 6/— 429&497 nm Double peak Yes >90 29% ∼7 13
NH2-GQD 2.5/1.1 420 nm Slight asymmetry Not stated 29% 32
2.5/1.1 535 nm Slight asymmetry 19%
GQD 5.3/1.2 515 nm Shoulder Yes 11.4% 82
GQD 5/— 550 nm Extremely narrow peak Not stated 20 91
GQD 3/0.85 460 nm Asymmetric Yes 120 92
NH2OH-GQD 3/0.85 420 nm Asymmetric 105
Pyrazole-GQD 3/0.85 550 nm Asymmetric 100
GQD 4/1.5 510 nm Asymmetric Yes 105 93
GQD 5/— 430&540 nm Asymmetric / double peak Yes 100 14% 94
GQD 4/0.75 445&503 nm Double peak 95
GQD 3.1/1.3 475 nm Asymmetric Yes 130 1.2% 96
Carbide-GQD 3.1/1.3 440 nm Almost symmetric 110 3%
GQD 20/1.0 530 nm Shoulder Not stated 100 97
GQD 5.5/1.2 498 nm Almost symmetric Yes 98 11.7% 98
6.8/1.2 540 nm Asymmetric 120 4.8%
7.6/1.2 565 nm Asymmetric 100 2.2%
N-GQD 3/0.8 520 nm Asymmetric / shoulder Yes 130 31% 6.27 53
N-GQD 3.9/— 530 nm Broad / shoulder Yes 70 99
GQD 3/1.0 520 nm Asymmetric Yes 13.1% 100
N-GQD 5.3/— 520 nm Almost symmetric Yes >100 8.4% 69
GQD 15/0.5 520 nm Asymmetric Yes 80 4.04% 101
18/2.0 550 nm Asymmetric 70 2.29%
N-GQD 10.6/1.4 560 nm Asymmetric Yes >100 9.1% 102
GQD 15/1.4 460 nm Symmetric Slight ∼100 9% 103
PEG-GQD 13.3/— 440 nm Slight shoulder Yes 80 7.4% 70
N-GQD 4.5/1.2 500 nm Asymmetric / shoulders Yes 150 11.7% 104
4.5/1.2 450 nm Asymmetric / shoulders 115 22.9%
GQD 4/1.5 473 nm Asymmetric / shoulders Not stated >130 105
GQD 3/1.25 440 nm Asymmetric / shoulders Yes 80 10% 106
N-GQD 4/1.8 425 nm Asymmetric / shoulders Yes >85 107
N-GQD 3.2/1.0 516 nm Slight asymmetry / shoulder Yes 100 6.0% 2.1 – 8.1 34
3.6/2.0 446 nm Slight asymmetry / shoulder 90 6.5% 2.7 – 3.5
GQD 3.1/1 430 nm Slight asymmetry / shoulder 90 12.1% 3.9 – 4.4
N-GQD 3.5/— 425 nm Asymmetric / shoulder Yes 115 8.6% 71
GQD 4.2/1.5 458 nm Multiple shoulders Not stated 100 4.8% 108
N-GQD 3.8/1.5 440 nm Almost symmetric / shoulder 125 23.3%
N-GQD 4.5/— 705 nm Extremely narrow peak Yes >250 43
N-GQD 5.8/1.7 302, 542 Three distinct emissions Yes 105, 67 11.3% ∼1 44
& 915 nm All symmetric &107
NFS-GQDa 2/1.5 409, 435 Triple peak No 70% 68
& 465 nm
a Sodium, Fluorine and Sulphur co-doped GQDs
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effects is desirable for a fluorescent label, and thus the under-
standing of mechanisms of photo-induced fluorescence changes
can aid in developing advanced synthesis method for the produc-
tion of good-quality and highly-stable quantum dots.
In SQDs, the photo-induced reduction of fluorescence, or
photo-bleaching, has been linked to irreversible photo-oxidation
of the semiconductor material. The photo-oxidation causes a
gradual decrease of the effective diameter of the core of the quan-
tum dot, evidenced by a blue shift in its emission, and a formation
of quenching states at the surface of the quantum dot with a sub-
sequent reduction of the PLQY of the quantum dot124,125. On
the other hand, photo-induced improvements of fluorescence in
SQDs have been attributed to photo-annealing processes involv-
ing surface reconstructions121,126. Encapsulation of SQDs, for
example in layers of silica material, has been shown to reduce
photo-induced fluorescence changes123,127. For GQDs, no in-
depth experimental investigations into the mechanisms of photo-
induced fluorescence changes have been published to date; how-
ever, the vast majority of works quoting photostability data report
no observable changes of GQD fluorescence with prolonged expo-
sure31.
3 Chemical properties
3.1 Synthesis of quantum dots
SQDs synthesis. A number of SQD types can be produced in
aqueous environments to yield intrinsically water-soluble quan-
tum dots: ZnS, PbS, CdS, CdTe, Cd3As2, Zn3P2, among oth-
ers have been previously synthesised in this manner128–135. In
essence, aqueous synthesis of SQDs can be thought of as a pre-
cipitation reaction between cation and anion precursors in the
presence of a stabilising agent, which controls the precipitation
process and limits the growth of the precipitate to nanometer-
sized particles. Due to the relatively low temperature used during
the reaction, these QDs tend to have moderate QYs (typically 40-
50%), but do not require water-solubilisation treatments for ap-
plications such as fluorescent probes in biomedical applications.
In fact, biomolecules such as proteins, nucleotides, nucleic acids
and amino acids can be used as templates for the nanocrystal
growth or as surface capping ligands, producing biofunctional
SQDs in situ136–139. An excellent and extensive review of the
aqueous methods of SQD synthesis was published recently by L.
Jing et al.128 and readers are directed to it for further details
on the history and recent progress of aqueous synthesis methods,
as well as the mechanisms of crystal growth, surface passivation
techniques, doping methods and optical properties of SQDs pre-
pared in such a manner.
Synthesis of highly fluorescent SQDs is usually achieved by
organometallic chemistry involving pyrolysis of organometallic
precursors in a hot coordinating solvent in the presence of sta-
bilising ligands140–143. Pyrolysis of precursors causes supersat-
uration of constituent elements, and subsequent nucleation and
growth of the semiconductor nanocrystals, with the stabilising lig-
ands preventing the aggregation of nanocrystals into bulk semi-
conductor during the reaction. The high temperature of this
method ensures removal of defects and passivation of surfaces
during crystal growth, thus resulting in almost monodisperse,
highly passivated SQDs. The subsequent epitaxial growth of an
inorganic shell, composed from the semiconductor material of
higher band-gap, further passivates the surface and from herein
protects the core of the nanocrystal144,145, resulting in very high
QYs of SQDs grown by this method. However, application of
these quantum dots in biomedical applications requires a fur-
ther water-solubilisation treatment, which usually involves either
an exchange of the stabilising ligands of SQDs for short-chain
charged ligands or encapsulation of native SQDs in a layer of am-
phiphilic molecules5,141,146. In the case of the former, the passi-
vation of the surface is usually somewhat reduced by the process,
resulting in a pronounced decrease of the PLQY147, however,
the modified SQDs generally possess excellent solubility22–24. In
the case of the latter, the native surface passivation remains un-
touched yielding superior PLQYs and stability of SQDs, however,
the amphiphilic caps tend to be difficult to functionalise post-
encapsulation148, due to the ’bulkiness’ of amphiphilic molecules
used, yield large SQD with diameters greater than 25 nm149.
GQD synthesis. While SQDs are always produced via a
bottom-up method, both top-down and bottom-up approaches
can be used for the production of GQDs. The bottom-up
method, in this context sometimes referred to as carbonisa-
tion, involves pyrolysis of organic precursors, such as citric
acid, glucose, pyrenes and polyphenylenes, using either thermal
or microwave-assisted methods33,35,69,87,98,103,108,151,152 (Table
3). Depending on the procedure and precursors used, some
GQDs prepared by these methods may require further treat-
ments to make them water-dispersible. However, this is eas-
ily achieved by mild oxidation. Top-down methods, on the
other hand, involve exfoliation and/or cutting of carbon pre-
cursors, such as graphite83,150, graphene67,105, graphene ox-
ide71,86, carbon fibres88,153, carbon black101, fullerenes92 and
carbon nanotubes68, through the use of reducing or oxi-
dising agents. The cutting can be achieved either by hy-
drothermal13,32,67,86,94,100, solvothermal34,53,93,155, microwave-
assisted68,107 or electrochemical90,102,104–106,150 (Table 3). All
GQDs prepared by these methods are inherently water soluble
and thus require no further treatments. Unfortunately, to date,
no comprehensive studies have been published that critically as-
sess the merit of each technique or the effect synthesis parameters
have on the optical and chemical properties of prepared GQDs.
As a result, as of this moment, there is no clear direction that
can be pursued towards the development of a controlled synthe-
sis method for fabrication of GQDs with pre-determined chemi-
cal and optical properties. This is both due to a rather limited
amount of examples that exist in the literature, and a relatively
wide breadth of methods that have been reported to date. There-
fore, despite the fact that great advances have been made in this
area in recent years, synthesis of GQDs is still complex and time-
consuming.
3.2 Functionalisation and labeling strategies
Post-synthesis and solubilisation, QDs may undergo further chem-
ical modifications, primarily aimed at achieving targeted ap-
10 | 1–24Journal Name, [year], [vol.],
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Table 3 Synthesis methods for Graphene Quantum Dots
Probe typea Synthesis method Precursor Ref
GQDs Hydrothermal cutting and reduction Graphene oxide 94
PEG-GQDs Hydrothermal cutting and reduction PEGylated graphene oxide 70
GQDs Hydrothermal cutting and oxidation Graphene oxide 86
Amino-GQDs Hydrothermal cutting and exfoliation Graphene oxide 13,32
N-GQDs Hydrothermal cutting and exfoliation Reduced graphene oxide 71
GQDs Hydrothermal cutting Graphene 67
GQDs Electrochemical cutting Graphene 105,106
N-GQDs Electrochemical cutting Graphene 107
GQDs, PEG-GQDs Electrochemical cutting MWCNTs 90
GQDs Electrochemical oxidation Graphite 150
GQDs, N-GQDs Electrolysis Graphite 102
GQDs, N-edge GQDs Exfoliation and reduction Graphite powder 83
GQDs, N-GQDs Pyrolysis (acidic carbonisation) Pyrene 33
GQDs Pyrolysis (acidic carbonisation) Polyaromatic hydrocarbons 98
GQDs Pyrolysis (acidic carbonisation) Dendritic polyphenylene 151
GQDs Carbonisation (pyrolysis) Citric acid 103
N-GQDs Carbonisation (pyrolysis) Citric acid 108,152
N-GQDs Microwave-assisted hydrothermal pyrolysis Glucose 44,53
GQDs Controlled pyrolysis Polyaromatic hydrocarbons 87
GQDs Self-limiting pyrolysis Polyaromatic hydrocarbons 35
GQDs Oxidative cutting Carbon fibres 88,89,91,153
GQDs Oxidative cutting & exfoliation Carbon black 101,154
GQDs Oxidative cutting & exfoliation Graphite 96,100
GQDs, PEG-GQDs Oxidative cutting & exfoliation Graphite 95
GQDs, N-edge GQDs Oxidative cutting & exfoliation Graphite 99
GQDs, N-edge GQDs Cage opening (oxidative cutting) Fullerene 92
N, F, S co-doped GQDs Microwave-assisted cutting in ionic liquid CNTs 68
N-GQDs Microwave-assisted oxidative cutting Graphene oxide 104
GQDs Solvothermal cutting Graphene oxide 82,93
GQDs, amino-GQDs Solvothermal cutting Graphene oxide 53
N-GQDs Solvothermal cutting Graphene oxide 34,155
GQDs Photo-Fenton reaction Graphene oxide 97
a GQDs refer to graphene quantum dots with oxygen-containing group at the edges (carboxyl, hydroxyl, etc.);
amino-GQDs refer to amino-functionalised GQDs; N-GQDs refer to nitrogen-doped GQDs;
N-edge GQDs refer to GQDs with N-containing edges and functional groups (predominantly not amino groups).
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proaches for drug delivery and bioimaging. In addition, a suitably
designed probe can have a higher internalisation, augmenting the
efficacy of the delivered drug, providing higher contrast during
bioimaging, significantly reducing the required dosages31, as well
as adding an additional modality to the system. Therefore, there
is a requirement for fluorescent probes to have well-established
libraries of functionalisation and labeling protocols. In this re-
spect, both SQDs and GQDs offer many opportunities since both
types of QDs usually have oxygenated and/or amino end-groups
(post-synthesis and solubilisation). This allows for straightfor-
ward further modification of their chemistry using standard car-
bodiimide cross-linker reactions. For example, both X. Wang
et al.156 and Chun-Lin Huang et al.157 have used carbodiimide
chemistry to functionalise GQDs with folic acid, thus imposing
specificity of their probes to folate receptor-overexpressing can-
cerous cells (e.g. HeLa), and similar examples also exist for SQDs
of various compositions and shapes58,158–161. A further point to
make is that attachment of molecular adaptors, such as strepta-
vidin, avidin, and biotin, are also possible using same standard
protocols, providing additional bioconjugation tools for ensuring
specificity of the fluorescent probes162. In fact, it is now possi-
ble to procure commercial SQDs that are pre-labeled with molec-
ular adaptors, greatly facilitating their implementation into dif-
ferential bioimaging studies. A noteworthy recent development
in the area of active targeting is a protocol for oriented conju-
gation of SQDs with single-domain antibodies to produce ultra-
small highly-specific fluorescent probes61,62,163–166.
Non-covalent functionalisation or loading of QDs is also possi-
ble, for example, by using electrostatic assembly, hydrogen bond-
ing, etc. In this case, however, the attachment of the loaded enti-
ties is not as strong and generally is found to be dependent on the
chemical environment of the QD, leaving a possibility of them be-
ing detached from the surface upon a change in the environment.
Indeed, in many cases, this fact has been exploited to achieve de-
livery and stimuli-responsive release of therapeutic drugs using
quantum dots as traceable drug delivery systems.
For SQDs, the non-covalent attachment is usually based on an
electrostatic attraction between the charged groups on their sur-
face and an oppositely-charged biomolecule or drug. For exam-
ple, Ellen R. Goldman et al.167 showed that it is possible to elec-
trostatically adsorb avidin to the surface of dihydrolipoic acid-
modified SQDs, allowing for facile conjugation of biotinylated
antibodies thereafter. Jianjiang Zhao et al.168 used electrostatic
assembly to attach survivin siRNA molecules to amino-PEG-SQDs
for downregulation of survivin gene expression in oral squamous
cell carcinoma cells, while Rijun Gui et al.169 used the same
method to load these type of SQDs with anticancer drug adri-
anycin for real-time monitoring of pH-dependent release of the
drug in HeLa cells. In a slightly different approach to loading
chemotherapy drugs to SQDs, Q. Yuan et al.170 electrostatically-
assembled ZnO SQDs with biodegradable chitosan – folic acid
conjugates in the presence of Doxorubicin hydrochloride (DOX)
drug, effectively trapping DOX in the SQD-chitosan-folic acid net-
work. Upon a change of pH, the DOX drug was released from the
network due to a shift in the equilibrium of positive and negative
charges within the complex.
DOX is also a popular drug of choice for loading onto
GQDs93,156,157,171, although in this case the loading is typically
performed via pi-pi stacking – staking of molecules based on at-
tractive non-covalent forces between the aromatic rings contained
within them. This ability of GQDs is of a great advantage since
it facilitates loading of somewhat hydrophobic drugs onto GQDs
without any modification of the drug, which simultaneously in-
creases the drug’s solubility in physiologically relevant media172
and endows it with traceability. It can also impose a specificity to
drug’s delivery if GQD is pre-functionalised with a biorecognition
element.
Furthermore, for both SQDs and GQDs, a combination of above
methods can be used to develop highly multi-modal fluorescent
probes. For example, Chun-Lin Huang et al.157 used carbodiimide
chemistry to graft onto GQDs an active targeting moiety in the
form of folic acid, which imposed specificity of the probes to folate
receptor-overexpressing cancerous cells. They also covalently at-
tached a chelating agent for paramagnetic ions, in the form of di-
ethlyene triamine penteaacetic acid, which enabled MR imaging
ability of this platform. Finally, DOX was loaded onto the GQDs
for the therapeutical purpose. In principle, in this manner, it is
possible to develop theranostic agents that amalgamate any com-
bination of the possible therapeutical properties (photodynamic,
photothermal, chemotherapy) with a number of imaging capabil-
ities (photoacoustic, photoluminescent, magnetic resonance).
3.3 Photoreactivity
In general, it is undesirable that a fluorescent probe undergoes
any chemical changes or becomes chemically active in its envi-
ronment upon photoexcitation. Such a property can, however, be
exploited in the case where photoinduced chemical activity con-
stitutes a production of reactive oxygen or other species that can
attack and cause the destruction of cell membranes. In fact, Pho-
todynamic Therapy (PDT) of cancer relies on exactly this process.
The co-localisation of the drug, known as photosensitiser (PS),
and a source of its photoexcitation results in increased selectivity
of PDT compared to other therapies, with a consequential reduc-
tion of associated side-effects173–176.
There are two main routes by which the highly reactive species
can be produced upon excitation of PS. The first route, type I,
involves an electron or hydrogen transfer and typically results in
the production of charged reactive species such as superoxides
and hydroxyl radicals. The second route (type II) is by triplet
energy transfer (TET) between the PS and ground (triplet) state
of the oxygen molecule, resulting in the production of highly re-
active and cytotoxic singlet oxygen (1O2)177–179. It is generally
accepted that singlet oxygen is primarily responsible for cell death
in PDT180,181 and, although contributions from species produced
via the type I route are not negligible, it is customary to measure
the efficacy of a PS drug by evaluating its singlet-oxygen yield182.
Both SQDs and GQDs have been proposed for use as sensitisers
in PDT of cancer. SQDs by themselves have been shown to pro-
duce ROS upon excitation but with efficiencies ∼10 times less
than that of conventional PS drugs183–185. Furthermore, SQDs
capable of generating ROSs tend to be of the core-only type, due
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to the requirement of easy and close access of oxygen for charge
and energy transfer from SQDs. Such SQDs are inherently less
chemically and photo-stable compared to core-shell SQDs, and
therefore, the lack of efficiency cannot be overcome by the ar-
gument of higher photostability of SQDs. A more promising ap-
proach in this area has been the employment of SQDs as a combi-
natory drug-carrier and light-harvesting system, in which a con-
ventional PS drug is attached to the surface of the SQDs. In this
configuration, the drug can be excited directly, depending on the
wavelength used, but also through the non-radiative transfer of
energy from SQDs. This effectively increases the overall absorp-
tion cross-section of the drug and the corresponding functional
spectral range. Both electrostatic and covalent conjugates have
been explored, involving type I and type II reactions, with re-
ports of both increased and decreased efficiencies of ROS produc-
tion118–123,125–130. The overall change in efficiency depends on
the interplay between the possible photophysical interactions be-
tween the SQDs and the PS drug, i.e. the energy transfer and
triplet-state quenching processes186. Even in the absence of ef-
ficient energy transfer, the use of SQDs as drug-delivery vehicles
is a promising avenue, since their broad absorption bands allow
the simultaneous visualisation of cancerous tissue and the photo-
activation of the PS drug in a spectrally-independent manner.
Regarding GQDs, many works reference their use for PDT ap-
plications but these are usually in the context of multi-modal sys-
tems187–191, where their use as PDT agents is in addition to other
modalities such as a drug delivery carrier for a chemotherapy
drug, as opposed to the inherent bi-modality of GQDs as imag-
ing and PDT agents. In fact, very few works directly evaluate the
efficiency of GQDs as PS drugs by measuring their singlet-oxygen
yield. For example, Markovic et al.150 and Jovanovic et al.192
both used the Electron Paramagnetic Resonance measurements
to monitor singlet-oxygen production by GQDs, however, neither
compared their results to a traditional PS of known singlet oxy-
gen yield. In majority cases where the performance of GQDs was
compared to standard PSs, the rate of singlet oxygen generation
by GQDs was determined to be significantly smaller72,191,193. Im-
portantly, however, a relatively recent study by Ge et al.194 found
that the singlet oxygen yield of pristine GQDs can exceed that of
the best performing traditional PSs. The key factor determining
the efficiency of GQDs seems to be their functionalisation or en-
capsulation. For example, in their work on the use of GQDs as
two-photon PDT agents, Kuo et al.72 quote a value for 0.51 for
the singlet oxygen yield of antibody-functionalised GQDs, which
is significantly lower than the yield of 1.3 quoted in the study
of Ge et al.194. Similarly, PEG-encapsulated GQDs produced by
Chandra et al.90 were found to produce considerably less ROSs
compared to their un-capsulated counterparts, due to singlet oxy-
gen quenching. These works infer a strong interplay between the
effectiveness of GQDs as PSs and any chemical modification that
they undergo to ensure a specificity of their delivery to cancerous
tissues. An interesting approach to circumvent this issue could
be the use of cleavable shells decorated with bio-recognition ele-
ments, similar to those used by Li et al.195 for delivery and release
of chlorine e6 from GQDs under a tumour relevant conditions. In
general, however, more research is needed to quantitatively eval-
uate this link for different types of GQDs — only then the full
potential of GQDs as PDT agents can fully be realised.
3.4 Chemical stability
In terms of the chemical stability, the requirement for fluorescence
probes is one of stable fluorescence performance in the chemical
environment that these probes are utilised in; thus, the pH of the
medium, the temperature and the presence of any ions must be
considered. This is particularly important for in vivo applications,
where changes in fluorescent behaviour may be misinterpreted,
and the chemical degradation of the probes can have direct detri-
mental effects. That being said, both SQDs and GQDs are col-
loidal materials, and as such are expected to have optimal regions
of chemical environments for utilisation.
For example, the physical and chemical properties of SQDs
drastically depend on the experimental conditions used, such as
the pH of buffer solution used or bioconjugation reagents em-
ployed. The fluorescence of SQDs is known to be quenched un-
der acidic conditions, such as those in cellular endosomes, and to
be enhanced under basic conditions196. In the process of endo-
cytosis, the exposure of amphiphilic polymer-encapsulated SQDs
to the acidic environment in endosomes or lysosomes results in
the spectral shift towards the blue region197. However, this in-
stability can be resolved via surface modification strategies. For
example, in a study by Hu et al.196, CdSe/ZnS SQDs were func-
tionalised with a silica and amphiphilic polymer, which resulted
in a stable complex in a broad range of chemical conditions such
as the strongly acidic environment. In their work, Hu et al. ap-
plied these stable SQD compounds in combination with a pH sen-
sitive dye for pH sensing application, exemplifying how inherent
instabilities of SQDs can be integrated into sensing schemes.
The SQDs with less than 5.5 nm hydrodynamic diameter are
known to be rapidly cleared from the organism via urinary excre-
tion; however, this is undesirable in biomedical application, such
as drug delivery and bioimaging198,199. Functionalised SQDs,
such as those typically employed for bioimaging application, are
larger in hydrodynamic diameter than 5.5 nm and are uptaken
via reticuloendothelial systems. As a result, they remain in the
biological organisms for long periods of time197, making their
stability under physiological conditions a critical factor. Unfortu-
nately, SQDs are known to be quite unstable under certain phys-
iological, chemical and environmental conditions, halting their
full application for in vivo diagnostics and quantitative imaging.
This is of particular concern in view of the fact that most of the
SQDs are composed of carcinogenic compounds, such as Cd, the
release of which upon degradation may result in potentially high
toxicity200, although this is disputed among the research com-
munity (see next section). Nonetheless, functionalisation strate-
gies involving small molecule ligands201, and amphiphilic poly-
mers136,202–204, as well as encapsulation strategies using silica
material205–209, have all been previously employed in order to
make SQDs more soluble and stable in physiologically relevant
solutions.
Similarly to SQDs, and in the reflection of their colloidal nature,
GQDs are also generally reported to have fluorescence properties
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and aggregation behaviour dependent on the pH and tempera-
ture of their solutions, as well as the presence of ions in their
environment31. An interesting contrast to point out here is that
the latter dependency is somewhat selective to the types of ions
present. A study published by Li et al.153 investigated the stabil-
ity and aggregation kinetics of GQDs in different buffer conditions
(i.e., cation type/valence, pH values, and the combined effect of
cations and pH). The author has demonstrated that the presence
of divalent cations, such as Mg2+ and Ca2+, resulted in increased
aggregation of GQD plates, reflected in a negative nonlinear cor-
relation between a quantitative indicator for the evaluation of the
stability of NPs in aqueous solution – the critical coagulation con-
centration and pH values. In contrast, the monovalent cations
such as Na2+ and K+ did not affect GQD stability, and the posi-
tive linear correlation was observed between the critical coagula-
tion concentration and pH levels. In their work, the authors have
proposed a three-step mechanism of aggregation of GQDs in the
presence of divalent cations.
Another study by Guo et al.210 utilised rhodamine B derivative-
functionalized (RBD) GQDs for detection of Fe3+ ion in vitro, the
accumulation, and deficiency of which is known to lead to a num-
ber of health problems such as anaemia, cancers, and organ dys-
function211,212. The application of RBD-GQDs as Fe3+ turn-on
nanosensor in living cells was based on a fluorescence enhance-
ment effect in the presence of Fe3+ ions. The effect of several
other ions was also investigated, some of which were physiolog-
ically significant (Ca2+, Fe2+, K+); however, these did not show
a similar enhancement effect. Overall, the RBD-GQD complexes
were shown to have increased water solubility, sensitivity, bio-
compatibility, and photostability, when compared to Rhodamine
B dye under similar conditions.
4 Biocompatibility
Biocompatibility is perhaps the most important property of a
newly-developed material when considering its utilisation for
biomedical applications. It is usually evaluated by considering the
cytotoxicity (in vitro toxicity) of the material and through in vivo
studies that look at biodistribution, clearance routes and longterm
side effects post-injection. Biocompatibility is a highly complex
property that cannot be fully predicted based on the composition
of the material. For many colloidal nanomaterials, factors such as
nanoparticle size, shape, aspect ratio, surface functionalisation,
encapsulation layers, presence of external excitation source and
(especially) dose have all been found to have a profound effect.
This makes the direct comparison between the biocompatibilities
of SQDs and GQDs extremely difficult. Therefore, the first two
subsections of this discussion mainly focus on key findings for the
two types of QDs regarding their in vitro and in vivo toxicities.
The last subsection attempts to provide a more direct point of ref-
erence from which to view these results, by comparing the limit
of detection for confocal imaging applications and relating it to
the dose of QDs used in the toxicity studies.
4.1 Toxicity in vitro
A number of biocompatibility studies have been carried for both
SQDs and GQDs. With respect to the former, the toxicity of com-
monly used SQDs has raised a lot of concern due to the intrin-
sic toxicity of such Cd-containing quantum dots. Consequently,
recent years saw a shift in the scientific focus towards the devel-
opment of non-heavy metal based SQDs or their encapsulation
in protective layers, both of which have shown reduced toxic-
ity127,205,213,214. On the other hand, the demand for safer alter-
natives generated interest in carbon-based nanoprobes, including
graphene quantum dots, which promised intrinsic biocompatibil-
ity. However, some types of GQDs have been shown to be highly
photoreactive causing damage on a cellular level, but elucidating
that, independent of the intrinsic nature of the material used, the
toxicity of the final product is also dependent on other factors
such as surface modification, size, shape, dosage, and delivery
method10.
Another contributor to SQD’s toxicity in vitro and in vivo is the
free radical generation, such as singlet oxygen, hydroxyl radical
(.OH), superoxide anion (-O2), hydrogen peroxide (H2O2), and
peroxynitrite (-ONOO). SQDs are extremely photosensitive and
are known to transfer the energy to molecular oxygen forming
singlet oxygen, which reacts with water and catalyses the enzy-
matic reaction in order to produce reactive oxygen or nitrogen
species (ROS/RNS)215,216. The free radicals can cause damage
not only on the cellular level (cell apoptosis) but can also lead
to mutations in the DNA217,218. Some consider oxidative stress
to be the primal cause of toxicity of QDs in vitro. However, this
production of singlet oxygen can also be used to an advantage,
where this particular property showed potential in the application
of PDT for a more targeting cancer therapy219–221, as discussed
previously. In an attempt to reduce the toxicity of SQDs, shell
coating method has been applied on numerous occasions which,
as the name suggests, involves coating of SQD cores with shells of
another inorganic material (e.g. ZnS), small molecules, polymers,
proteins or silica9,127. The coatings allow for a slower transport
of oxygen to the core surface thus reducing the rate of ROS pro-
duction, however, they do not completely inhibit it and they tend
to be susceptible to degradation in the cellular environment.
GQDs, on the other hand, were first considered because of
their intrinsic low toxicity owing to their carbon-based compo-
sitions222, and they have since become an attractive target for
biomedical applications. However, even though GQDs have been
shown to have quite a low toxicity, it is not altogether absent.
Several in vitro studies were performed in order to evaluate the
cytotoxicity of GQDs and some of these can be found summarized
in Table 4. The most commonly cited origin of cytotoxicity in
GQDs is the photoinduced production of reactive oxygen species,
such as superoxide anions and singlet oxygen223,224. Production
of ROS has been linked to induced cytotoxicity and cell death
(apoptosis) via activation of a group of cysteine proteases called
caspases225,226. The oxidative stress and the damage caused
within the cells can, in turn, promote increased autophagy in or-
der to clear damaged cellular components. This is the first line of
defence for cells in case of nanoparticle-induced cytotoxicity227.
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Table 4 In vitro cytotoxicity studies using graphene quantum dots
Probe typea Cytotoxicity Length of Cell type Results Ref.
test(s) exposure
PEGylated GQDs WST-1, LDH 24 hr No indication of toxicity; 95
HeLa 95% viability at 160 µg.mL-1
A549 85% viability at 640 µg.mL-1
GQDs and hydrothermally WST-1 24 hr A549 ∼80% viability at 100 µg.mL-1 96
treated GQDs
GQDs MTT 24 hr MCF-7 >80% viability at 200 µg.mL-1 97
MGC-803 >70% viability at 200 µg.mL-1
GQDs (from pyrene) MTT 24 hr MCF-7 100% viability at <100 µg.mL-1 98
>90% viability at 500 µg.mL-1
N-doped GQDs Cell viability 24 hr HeLa ∼80% viability at 400 µg.mL-1 53
GQDs (rich in N and O groups) 24 hr RSC96 >90% viability at 0-100 µg.mL-1 85
>60% viability at 300 µg.mL-1
GQDs MTT 24 hr RSC96 >90% viability at 100 µg.mL-1 82
>80% viability at 400 µg.mL-1
N-GQDs SEIRA 20 min RBC At 50 µg.mL-1 disturbance of order and 155
conformation of lipid, possibly due to
incorporation of GQDs, resulting in
formation of echinocytes
GQDs MTT 24 hr THP-1 >93% viability at 0-100 µg.mL-1 100
82.5% viability at 200 µg.mL-1
48 hr >92% viability at 0-10 µg.mL-1
87.3% viability at 50 µg.mL-1
76.1% viability at 100 µg.mL-1
62.2% viability at 200 µg.mL-1
a Unless otherwise stated, GQDs were used as-prepared and contained the native oxygenated edges (carboxyl, hydroxyl, etc.)
In addition, it has been previously shown that cells exposed to
QDs express higher levels of L3B-II protein, which is a marker
for autophagy150,228. Analogous to the similar issue with SQDs,
attempts have been made to reduce ROS-related cytotoxicity of
GQDs through surface modification or encapsulation of GQDs in
protective layers. For example, crude GQDs were found to be
more cytotoxic compared to PEG-functionalised GQDs. This re-
duced toxicity could be a combined effect of PEG being more bio-
compatible and the larger size of PEG-GQDs90.
In the area of gene expression and genotoxicity, some detailed
research has been carried out for SQDs concluding that long expo-
sure to SQDs can lead to DNA damage, resulting in DNA mutation
and possibly leading to cancer and other side-effects209,231. How-
ever, only a limited number of studies were carried out examining
genotoxicity effect of GQDs. The only study to date that looked at
genotoxicity of GQDs has been that of C. Wu et al., in which flow
cytometry and cell cycle analysis of MCF-7 and MGC-803 cells
was used to demonstrate some damage to GQDs97. This area ur-
gently requires further investigations if GQDs are to be considered
for medical applications.
Another area that somewhat falls short on the scope and de-
tail of available information is that of cytotoxicity studies on cells
that are involved in inflammation, such as macrophages. This is
of particular importance for GQDs, as their counterparts graphene
and graphene oxide have been shown, in mice, to result in pul-
monary inflammation upon inhalation232,233. Even though the
level of resultant inflammation can be reduced through function-
alization of GQDs, the need for more detailed in vitro and in vivo
studies on cytotoxicity of GQDs is evident. Only one study ex-
ists that investigated the effect of GQDs on macrophage cell line
THP-1 by Qin et al., demonstrating that in activated THP-1 cells
GQDs result in induced ROS generation, increased apoptosis, au-
tophagy, and inflammatory response via p38MAPK and NF-kB me-
diated signaling pathways100.
In general, for both types of quantum dots, the cytotoxicity re-
sults point to strong dependencies on a number of parameters,
with favourable outcomes for quantum dots of either type encap-
sulated in protected layers and at reduced doses. For SQDs, the
main concern is the presence of Cd ions – a point which may be
rendered mute by the development of cadmium-free SQDs. For
GQDs, the main concern at the moment is lack of information,
although this is slowly being addressed with key dependencies
being gradually established. A recent review by S. Wang et al.234
neatly summarises some of these results, and the readers are di-
rected to it for further information.
4.2 Toxicity in vivo
One of the unique property of nanoparticles is that, due to their
small size, they are able to access the areas within a cell or body
that are difficult to penetrate. For example, nanoparticles that
are less than 100 nm in size can enter the cell, those that are
less than 40 nm can enter the nucleus of the cell and those that
are less than 35 nm can cross the blood-brain barrier235. Both
types of quantum dots are very small in size and can easily cross
the blood-brain barrier, which can potentially lead to severe side-
effects236. Consequently, detailed in vivo toxicity studies are ab-
solutely crucial; yet, only a limited number of studies have looked
at in vivo toxicity of SQDs and GQDs.
Perhaps one of the more comprehensive studies involving SQDs
has been one of Hauck et al.229, where an assessment of in vivo
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Fig. 8 Biodistribution of semiconductor (a,b) and graphene (c-e) quantum dots in mice. (a) Biodistribution of carboxyl CdSe/ZnS quantum dots
in Sprague-Dawley rats, deducted from levels of Cd in the tissue. Reprinted with permission from Hauck et al. 229 Copyright (2017) John Wiley and
Sons. (b) Digestion and ultracentrifucation studies of CdSe/ZnS studies in Sprague Dawlet rats, showing ACP-AES signal of spleen (A, C, F and I),
liver (B, D, G and J) in tissue (A-D), with (A, B) and without (C, D) prior dosing of quantum dots and in positive controls (SQDs in PBS buffer: E-G and
Cd spiked aqueous solution: H-J). Reprinted with permission from H. C. Fischer et al. 230 Copyright (2017) John Wiley and Sons. (c-e) Biodistribution
of carboxylated GQDs in Balb/c nude mice (c) in vivo, at various times post-injection, (d) 2 hours post-injection from isolated organs, and (e) ex-vivo,
24 hours post-injection into tomour site, monitored via GQD fluorescence. Reprinted with permission from M. Nurunnabi et al. 89 Copyright (2017)
American Chemical Society.
toxicity was carried out for CdSe-ZnS core-shell QDs with dif-
ferent surface functionalization groups, using female Sprague-
Dawley rats as in vivo model. In this study, several toxicity indi-
cators were examined, including animal survival, biodistribution,
animal mass, haematology, clinical biochemistry, and organ his-
tology over short and long periods of time (>80 days). The study
showed that, in the short-term, SQDs accumulate primarily in the
spleen and liver, as is expected during clearance from the blood by
cells of the mononuclear phagocytic system; after several weeks,
the authors hypothesised, SQDs partially break down into their
constituent elements, causing the accumulation of Cd in the kid-
neys (Figure 8a). This is a point of worry, since the heavy metal
ions, such as Cd2+, released in the process degradation of SQDs
are known to bind to heavy molecular weight proteins, such as
metallothionein. The clearance of these protein-heavy metal ion
complexes from the organism is a very slow process; for example,
metallothionein-Cd complexes were shown to have a biological
lifetime in the kidney of 38 years237. However, Hauck et al. con-
cluded that the levels of Cd accumulation observed in their study
were insufficient to cause any significant toxicity.
In another study, H. C. Fischer et al.230 have examined biodis-
tribution, sequestration, and clearance of CdSe-ZnS SQDs in the
same rat in vivo model. They found that the short-term biodistri-
bution of SQDs depended strongly on their functionalisation, with
bovine serum albumin-conjugated SQDs being uptaken quicker by
the liver than those that were stabilised by mercaptoundecanoic
acid cross-linked with lysine. Interestingly, they did not observe
degradation of the SQDs, unlike the study mentioned above, nor
were they excreted in the short term (Figure 8b), suggesting that
SQDs are sequestered and later re-distributed in vivo.
Concerning GQD’s in vivo toxicity, there is a rather under-
whelming amount of works on this subject and the results are
often contradictory to each other, perhaps in reflection of the
vast amount of dependencies that biocompatibility has on differ-
ent nanoparticle parameters. By far the two most comprehen-
sive studies of in vivo toxicities of GQDs were performed by Nu-
runnabi et al.89 and Chong et al.95, both opting to use Balb/c
mice for their studies. Nurunnabi et al. used carboxylated GQDs
synthesised by exfoliation of carbon fiber in acid and injected in-
travenously, while Chong et al. use Cy-7-labelled PEGylated GQDs
synthesised by oxidative cutting from graphite and injected either
intravenously or interperitoneally. While Chong et al. observed no
differences in biodistribution depending on injection site, there
were vast differences in biodistribution between the two types of
GQDs. The PEGylated GQDs, injected at a dose of 15 mg.kg-1
accumulated primarily in kidneys with low levels of fluorescence
reported for all other organs and the tumour site. On the other
hand, the biodistribution of carboxylated GQDs was more even
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across all organs (Figure 8c-e), with a significant proportion be-
ing accumulated in the tumour site. Furthermore, the proportion
of GQDs accumulating in spleen and lung increased significantly
at a higher dose of 10 mg.kg-1 (when compared to 5 mg.kg-1 ).
This is worrying since the former could impact the modulation
of the immune system and the latter could lead to pulmonary in-
flammations, as was previously observed for GQDs’ counterparts
graphene oxide222,238.
The clearance of GQDs from body was not well reported by
Nurunnabi et al. who do not provide any data apart from time-
stamped in vivo images (Figure 8c) and noting that the fluores-
cence signal decreased to non-observable levels in 24 hours and
that fluorescence levels of ex vivo images of dissected organs at
24 hours post-injection were lower than those at 12 hours post-
injection. They attribute that to the excretion of GQDs from the
body but do mention that loss of fluorescence in time could also
be a factor. Indeed, as GQDs partly consist of aromatic carbons,
their metabolism cannot be ignored as a possible source of loss of
fluorescence. However, the authors make no attempts to resolve
this issue.
Chong et al. do provide trends for all major organs for the du-
ration of their study (48 hours). The results show a rapid clear-
ance of GQDs from kidneys. This result, combined with signifi-
cant levels fluorescence in the urine and its absence in the retic-
uloendothelial system, led to the conclusion of fast metabolism
through kidneys as the main mechanism of body clearance for
PEGylated GQDs. However, one issue that the authors do not dis-
cuss is the trends observed for other organs. Specifically, the fact
that fluorescence levels in liver, heart and lung remain more or
less constant over the 24 hours, while those in spleen seem to
increase over the same time period. These facts suggest that a
proportion of GQDs is sequestered and then redistributed. Given
the short length of the study one cannot rule out this possibility,
or the possible long-term side-effects due to the presence of these
GQDs in the spleen.
Both studies did perform long-term haematological and bio-
chemical blood analysis, with tests conducted over periods of 22
and 40 days, with injections every other day over first 14 days
at a dose of 5 and 10 mg.kg-1 and 20 mg.kg-1 respectively by
Nurunnabi et al. and Chong et al. Both report all marker levels
within normal ranges and no indicators of any obvious toxicity.
Similarly, both report no major histopathological abnormalities
and legions for the two types of GQDs, with the exception of mod-
erate pathological changes in the liver and lung for carboxylated
GQDs at 21 days post-injection for the 10 mg.kg-1 dose. These re-
sults do suggest low in vivo toxicity of GQDs, especially those that
are encapsulated. However, they also highlight the differences be-
tween GQDs depending on some basic parameters (such as size,
functionalisation and dose) and call for further longterm studies
involving different types of GQDs so that a full understanding of
GQD uptake, biodistribution, toxicity and clearance can be devel-
oped.
4.3 Comparison of limits of detection
When performing confocal imaging of live animals or tissues, the
limit of detection (LOD) relates to the minimum signal that must
reach the detector to be able to distinguish it from the back-
ground (e.g. autofluorescence). In general, the detected signal
will depend on: the attenuation of excitation source by tissues,
the probe’s (linear or nonlinear) absorption coefficient at the ex-
citation wavelength, the concentration or amount of the probe
that is excited (i.e. dosage), the PLQY of the probe, the attenu-
ation of the emitted signal by tissues, and the detector efficiency
at the emission wavelength. For the sake of a more direct com-
parison between the probes, the latter is assumed to be the same
across the considered below spectral range. We further limit our
discussion to typical QD samples, i.e. those that can be consid-
ered representative of each QD type. For SQDs, this is a sample
that emits at 655 nm with PLQY of ∼75 %, and has a Stokes’ shift
of ∼50 nm, yielding the optimal excitation wavelength of 600 nm
and a corresponding extinction coefficient of ∼3x105 M-1 cm-1
(according to Peng et al.88). For GQDs, this is a sample emitting
at 520 nm with ∼10 % PLQY and 100 nm Stokes’ shift, yielding
the optimal excitation wavelength of 420 nm. The extinction co-
efficient of GQDs is taken to be same as that for the SQD sample
since the extinction coefficients of GQDs are not well reported,
but those few that are reported are in the same range as those of
SQDs (Table 1).
Considering only the photophysical properties of the quantum
dots, the signal that can be obtained with SQDs is 7.5 times larger
than if using GQDs at the same concentration. However, the at-
tenuation of the excitation source by tissues at the optimal ex-
citation wavelength for GQDs (420 nm) is ∼20 times stronger
when compared to that at the optimal excitation wavelength of
SQDs (600 nm), using breast tissue as an example239. Similarly,
the emitted signal will also be attenuated ∼5 times more at the
wavelength of GQD emission (520 nm) compared to attenuation
at the wavelength of SQD emission (650 nm). Therefore, for
equal excitation powers, probe concentrations and detector effi-
ciencies, the fluorescence signal detected when using GQDs as in
vivo bioimaging probes will be almost three orders of magnitude
lower (∼750).
This has implications for the LOD for bioimaging: to obtain the
same level of contrast during imaging, the dose requirement for
a typical GQD sample is three orders of magnitude larger than
that for a typical SQD sample. Using an LOD value for SQDs
emitting at 655 nm reported by M. Roy et al.240 (0.57 pmol.g-1,
or a dose of ∼0.5 mg.kg-1), the GQD dose required to achieve
the same level of contrast would be 35 mg.kg-1, taking into ac-
count their lower molar weights (∼10 times lower than SQDs).
Importantly, this value is higher than those considered in toxicity
studies in the section above; and for practical applications, doses
even larger that this will need to be used. Therefore, despite the
very rough nature of these estimates, one can argue that most
of the toxicological studies involving GQDs are not appropriate
to be able to draw any deterministic conclusions regarding their
longterm in vivo toxicity, as the dosages used are less than those
required for practical applications.
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Fig. 9 Number of publications on the use of QDs for cancer
therapy and diagnosis. Statistics were taken from Web of Science
searches on the topic, including either SQD (red) or GQDs (black) as
keywords.
5 Conclusions
Although inherently of very different nature, both types of QDs
are attractive candidates for utilisation as fluorescence labels for
diagnosis and therapy of cancer. Their distinguishing physio-
chemical properties make each type of QDs more suitable to spe-
cific applications or determine the mode of their implementation
to achieve a specific task. For example, the symmetric and size-
dependent photoluminescence band of SQDs, combined with ex-
tremely wide absorption bands make them ideal candidates for
multiplexing applications. This would be difficult to achieve with
the quasi-molecular fluorescence of GQDs that tends to be exci-
tation wavelength dependent. On the other hand, pristine GQDs
are excellent producers of ROSs and thus show great potential for
photodynamic therapy applications.
However, despite their considerable promise, a number of is-
sues remain to be addressed. For example, for SQDs there exists
a number of well-developed synthesis methods and an extensive
library of functionalisation and labelling protocols. However, typ-
ical PLQYs of cadmium-free SQDs remain to be quite low and
very few of these have emissions in the NIR – there is an urgent
need to develop efficient synthesis methods for this type of SQDS.
Another area that somewhat deficient in examples is that of mul-
tiplexed applications of SQDs – this is surprising since SQDs are
ideal candidates for such mode of utilization. Furthermore, both
graphene and semiconductor QDs lack characterisation in terms
of their nonlinear properties and their photoreactivity. This is
an issue because new probes such as QDs can be considered for
real-life applications only when all interdependencies between
the physical and chemical properties of QDs have been identified.
This is particularly problematic for GQDs, for which there is a gen-
eral lack of information on a number of fronts, including their key
optical properties (PLQYs, extinction coefficients, lifetimes etc.),
mechanisms of photobrightnening and photobleaching, the inter-
relation of optical properties to synthesis method and mechanism
of ROS generation. However, GQDs are relative new-comers to
the field and the rate of publications on their use for cancer ther-
apy and diagnosis is increasing quickly, unlike that of SQDs which
seems to have saturated over the last few years (Figure 9). It is
thus expected that many of the knowledge gaps mentioned above
will be addressed.
A final note that we would like to make here relates to the lack
of toxicity information for both types of quantum dots. This is a
worrying factor that urgently needs addressing. Any application
of QDs for biomedical purposes is prerequisite upon an extensive
study of their biocompatibility and cytotoxicity. Unfortunately,
there is no standardised methodology for such assessment that
currently exists and it is, therefore, impossible to compare re-
sults obtained from different biomedical applications that can be
found in the literature. This is of note because the toxicity of the
vast range of nanomaterials used in literature has been shown to
depend heavily on their composition, size, and methods of deliv-
ery, shape, chemical structure, surface properties such as charge,
biodistribution, biodegradation, and many more. In this respect,
the functionalization of QDs should consider the target and route
of administration, i.e. intravenous or oral, and adjust the func-
tionalization process accordingly. Depending on the size, surface
functionalization, charge and hydrophobicity QDs may elicit dif-
ferent immune reactions. For cancer therapy applications, the
effect of QDs in terms of cytotoxicity should be studied both in
cancerous tissues and in normal cells that may come in contact
with QDs on their route to the target, and in terms of the effect of
their excretion in exosomes after drug release. Furthermore, the
cytotoxicity should be studied over a long-term exposure since
any long-term cytotoxicity may lead to disruption of normal bod-
ily functions on a cellular level and may eventually result in dis-
ease or other side-effects, even if QDs are not toxic immediately
following administration. Finally, the photophysical properties of
the probes need to be considered when determining the appropri-
ate dosage ranges for toxicity studies.
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